Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends NBRV vs. SCYX, ETTX, VSTM, GLSI, TSVT, FULC, ACTU, GALT, LFVN, and NKTXShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include SCYNEXIS (SCYX), Entasis Therapeutics (ETTX), Verastem (VSTM), Greenwich LifeSciences (GLSI), 2seventy bio (TSVT), Fulcrum Therapeutics (FULC), Actuate Therapeutics (ACTU), Galectin Therapeutics (GALT), LifeVantage (LFVN), and Nkarta (NKTX). These companies are all part of the "medical" sector. Nabriva Therapeutics vs. SCYNEXIS Entasis Therapeutics Verastem Greenwich LifeSciences 2seventy bio Fulcrum Therapeutics Actuate Therapeutics Galectin Therapeutics LifeVantage Nkarta Nabriva Therapeutics (NASDAQ:NBRV) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Which has more volatility and risk, NBRV or SCYX? Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Does the media refer more to NBRV or SCYX? In the previous week, Nabriva Therapeutics had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for Nabriva Therapeutics and 0 mentions for SCYNEXIS. Nabriva Therapeutics' average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score. Company Overall Sentiment Nabriva Therapeutics Neutral SCYNEXIS Neutral Does the MarketBeat Community believe in NBRV or SCYX? SCYNEXIS received 112 more outperform votes than Nabriva Therapeutics when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 56.22% of users gave Nabriva Therapeutics an outperform vote. CompanyUnderperformOutperformNabriva TherapeuticsOutperform Votes39356.22% Underperform Votes30643.78% SCYNEXISOutperform Votes50570.04% Underperform Votes21629.96% Do insiders and institutionals believe in NBRV or SCYX? 0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 2.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is NBRV or SCYX more profitable? Nabriva Therapeutics has a net margin of -148.11% compared to SCYNEXIS's net margin of -425.41%. SCYNEXIS's return on equity of -66.21% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% SCYNEXIS -425.41%-66.21%-38.84% Which has higher valuation and earnings, NBRV or SCYX? SCYNEXIS has lower revenue, but higher earnings than Nabriva Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ASCYNEXIS$8.57M5.32$67.04M-$0.74-1.62 Do analysts rate NBRV or SCYX? Given Nabriva Therapeutics' higher probable upside, research analysts plainly believe Nabriva Therapeutics is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySCYNEXIS beats Nabriva Therapeutics on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-0.0711.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / BookN/A10.377.096.50Net Income-$57.19M$153.60M$119.65M$226.22M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0739Analyst ForecastNews CoverageSCYXSCYNEXIS1.2553 of 5 stars$1.21+1.7%N/A-25.9%$45.92M$8.57M-1.6160ETTXEntasis TherapeuticsN/A$2.19flatN/A+0.0%$104.80M$7M-1.9651VSTMVerastem2.7519 of 5 stars$4.05+3.1%$12.50+208.6%-37.8%$180.27M$2.60M0.0050Analyst DowngradeAnalyst RevisionNews CoverageGLSIGreenwich LifeSciences1.6972 of 5 stars$13.70+5.6%$38.00+177.4%+19.4%$180.16MN/A-16.213TSVT2seventy bio2.3879 of 5 stars$3.45+9.2%$9.00+160.9%+107.5%$177.99M$100.39M-1.82440FULCFulcrum Therapeutics3.5831 of 5 stars$3.26+9.8%$9.33+186.3%-28.6%$175.84M$2.81M-10.29100ACTUActuate TherapeuticsN/A$9.00flatN/AN/A$175.77MN/A0.0010GALTGalectin Therapeutics1.7197 of 5 stars$2.78+2.2%$11.00+295.7%+36.9%$174.47MN/A-3.759Analyst UpgradeLFVNLifeVantage3.0517 of 5 stars$13.87+5.4%N/A+157.7%$173.72M$196.01M41.13260NKTXNkarta3.3035 of 5 stars$2.44flat$15.00+514.8%-5.4%$172.19MN/A-1.30140Analyst ForecastNews Coverage Related Companies and Tools Related Companies SCYX Alternatives ETTX Alternatives VSTM Alternatives GLSI Alternatives TSVT Alternatives FULC Alternatives ACTU Alternatives GALT Alternatives LFVN Alternatives NKTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBRV) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
